1402438-74-7

Basic information

• Product Name: PF-06273340
• CAS NO: 1402438-74-7
• Molecular Weight: 479.926
• Mol File: 1402438-74-7.mol
• Article Data: 2

Chemical Properties

• Density: 1.47±0.1 g/cm3(Predicted)
• CAS DataBase Reference: PF-06273340(CAS DataBase Reference)
• NIST Chemistry Reference: PF-06273340(1402438-74-7)
• EPA Substance Registry System: PF-06273340(1402438-74-7)

Safety Data

• Hazardous Substances Data: 1402438-74-7(Hazardous Substances Data)

Usage

General Description

PF-06273340 is a chemical compound that has been developed as a potential treatment for type 2 diabetes. It works by targeting the glucagon receptor, which plays a key role in regulating blood sugar levels. By blocking the glucagon receptor, PF-06273340 may help to reduce the production of glucose in the liver and improve insulin sensitivity in muscle and fat tissue. This could lead to better control of blood sugar levels in patients with type 2 diabetes. Clinical trials have shown promising results for the efficacy and safety of PF-06273340, making it a potential candidate for the treatment of type 2 diabetes in the future.

Upstream product

• 1402445-23-1 (5-aminopyridin-3-yl){7-(2-{[tert-butyl(dimethyl)silyl]oxy}-1,1-dimethylethyl)-2-[(2,4-dimethoxybenzyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}methanone 
• 335654-06-3 2-chloro-7H-pyrrolo[2,3-d]pyrimidine 
• 1060815-90-8 2-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine 
• 183608-47-1 N-methyl-N-methoxy-5-bromopyridine-3-carboxamide 
• 1000522-43-9 2-(5-chloropyridin-2-yl)acetic acid 

Relevant articles and documents

The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain

The neurotrophin family of growth factors, comprised of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4), is implicated in the physiology of chronic pain. Given the clinical efficacy of anti-NGF monoclonal antibody (mAb) therapies, there is significant interest in the development of small molecule modulators of neurotrophin activity. Neurotrophins signal through the tropomyosin related kinase (Trk) family of tyrosine kinase receptors, hence Trk kinase inhibition represents a potentially druggable point of intervention. To deliver the safety profile required for chronic, nonlife threatening pain indications, highly kinase-selective Trk inhibitors with minimal brain availability are sought. Herein we describe how the use of SBDD, 2D QSAR models, and matched molecular pair data in compound design enabled the delivery of the highly potent, kinase-selective, and peripherally restricted clinical candidate PF-06273340.